Ascendis Pharma Announces the Appointment of Thomas P. Soloway as Chief Financial Officer

   Ascendis Pharma Announces the Appointment of Thomas P. Soloway as Chief
                              Financial Officer

PR Newswire

COPENHAGEN, Denmark, Jan. 9, 2014

COPENHAGEN, Denmark, Jan. 9, 2014 /PRNewswire/ -- Ascendis Pharma A/S
announced today that Thomas P. Soloway has been appointed Chief Financial
Officer. Mr. Soloway joins the company after holding the positions of Chief
Financial Officer and Chief Operating Officer at Transcept Pharmaceuticals,

"Tom's strong background in both the US capital markets and operating
positions will be an important asset to Ascendis," stated Jan Moller
Mikkelsen, Chief Executive Officer. "Tom will play a key leadership role as
we continue to execute on our strategic plan. Tom joins our organization at a
particularly exciting time. In addition to our large pharma partnerships in
diabetes, pulmonary arterial hypertension and ophthalmology, we recently
initiated a Phase 2 trial with our human growth hormone product in children,
and launched a new initiative in the large and growing osteoarthritis market."

Mr. Soloway said, "What attracts me to Ascendis is its experienced leadership
team, a strong pipeline of development stage programs, and a clinically proven
prodrug technology platform that has been commercially validated by large
pharma partnerships. I am excited to join a company with a track record of
strong execution and look forward to contributing to our continued growth."

Mr. Soloway joins Ascendis from Transcept Pharmaceuticals, Inc. where he was a
co-founder of the company and served initially as Chief Financial Officer and
later as Executive Vice President and Chief Operating Officer. In these
roles, Mr. Soloway led all investor relations activities and was a key member
of the executive management team overseeing clinical development, regulatory
affairs, pharmaceutical sciences, manufacturing and all financial activities.
Mr. Soloway led Transcept through its transition from a private to public
company and raised more than $200 million for Transcept during his tenure.
Earlier in his career, Mr. Soloway was a Principal at Montreux Equity
Partners, a life sciences focused venture capital firm. Mr. Soloway received a
Bachelor of Science in Entrepreneurial Studies from the University of Southern
California and a Masters of Business Administration from Georgetown

About Ascendis Pharma

Ascendis Pharma develops differentiated prodrug versions of high-value drugs.
The company's proprietary TransCon technology is used to generate product
candidates that are improved versions of existing drugs, yielding more
effective, lower-risk therapeutics with new patent life.

Ascendis Pharma has a diversified and balanced high-value pipeline. Ascendis
has strategic partnerships with Sanofi in diabetes, United Therapeutics in
pulmonary arterial hypertension and an undisclosed market leader in the field
of ophthalmology.

For more information, visit 

Thomas P. Soloway
Chief Financial Officer, Ascendis Pharma A/S
Phone: 415.699.9924

SOURCE Ascendis Pharma

Press spacebar to pause and continue. Press esc to stop.